First FDA approval for cannabidiol-based drug moves closer

20 April 2018
2019_biotech_test_vial_discovery_big

A predicted blockbuster has moved closer to market with the news that a US Food and Drug Administration (FDA) advisory committee has recommended GW Pharmaceuticals’ (Nasdaq: GWPH) Epidiolex (plant-derived cannabidiol) for approval as an adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

Of wider interest is the fact that, if approved, Epidiolex would be the first pharmaceutical formulation of purified, plant-based cannabidiol oral solution, a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs.

LGS and Dravet syndrome, which develop in childhood, are forms of epilepsy with high morbidity and mortality rates. If the agency agrees with the unanimous recommendation of its committee, Epidiolex would be the first-ever FDA-approved medicine for Dravet syndrome patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology